CRBU News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CR

Mkt Cap

$50.0M

Volume

2.71M

Next Earnings

November 11th

Loading chart

CR

CRBUCaribou Biosciences, Inc. Common Stock

CRBU

Pay with—

Available Balance0.00

CR

Mkt Cap

$50.4M

Volume

2.71M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Looking for Earnings Beat? Buy These 5 Top-Ranked StocksAn analysis of stocks with strong potential to deliver earnings surprises identifies five companies: Allstate (ALL), Wayfair (W), BILL Holdings (BILL), Twilio (TWLO), and Caribou Biosciences (CRBU). These stocks were selected based on positive earnings surprise history, strong Zacks Rank ratings, positive Earnings ESP, and solid long-term growth prospects. Historical data shows these companies have consistently beaten market expectations, with Allstate averaging a 45.34% earnings surprise over the past four quarters.Zacks Investment Research · Aug 31, 2026

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceCaribou Biosciences announced positive clinical data for its CRISPR-based CAR-T cell therapies. Vispa-cel demonstrated an 82% overall response rate and 67% complete response rate in second-line large B cell lymphoma patients with a 17.1-month median progression-free survival. CB-011 showed an 83% complete response rate and 91% MRD negativity in heavily pretreated multiple myeloma patients, with 50% maintaining complete response at 15 months.GlobeNewswire Inc. · Jun 29, 2026

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual MeetingCaribou Biosciences reported positive clinical data for CB-011, its off-the-shelf BCMA-targeted CAR-T cell therapy for relapsed/refractory multiple myeloma. In 12 BCMA-naïve patients at the recommended dose, CB-011 achieved 83% complete response rate, 91% MRD negativity, and 50% of patients remained in complete response at 15 months with a manageable safety profile. The company also presented a case study of a patient previously treated with an approved CAR-T therapy who achieved complete response with CB-011. Dose expansion data is expected in H2 2026.GlobeNewswire Inc. · Jun 11, 2026

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment TrendsThe global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target effects and expansion into agricultural biotechnology.GlobeNewswire Inc. · Jan 22, 2026

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple MyelomaCaribou Biosciences reported promising first clinical data for CB-011, an off-the-shelf allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma, with 92% overall response rate and a manageable safety profile.GlobeNewswire Inc. · Nov 3, 2025

CRISPR Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsightCRISPR therapies are showing significant potential with over 25 key companies developing 30+ pipeline therapies targeting genetic disorders, with promising clinical trials across various disease areas.GlobeNewswire Inc. · Oct 2, 2025

Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS InsiderThe global gene editing market is projected to grow from USD 6.09 billion in 2024 to USD 15.46 billion by 2032, driven by CRISPR technology advances, therapeutic applications, and significant research funding, with North America leading market development.GlobeNewswire Inc. · Sep 2, 2025

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmLaw firm investigating potential claims against Caribou Biosciences regarding allegedly misleading statements about its cell therapy product CB-010's safety, efficacy, and financial prospects during July 2023-2024 period.GlobeNewswire Inc. · Jul 25, 2025

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care ConferenceCaribou Biosciences, a clinical-stage CRISPR genome-editing biopharmaceutical company, announced a strategic pipeline prioritization with a focus on its CB-010 and CB-011 oncology programs. The company expects this move to extend its cash runway by one year into H2 2027.GlobeNewswire Inc. · May 6, 2025

CRBU DEADLINE NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Caribou Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 24 Deadline in Securities Class Action – CRBUCaribou Biosciences, Inc. is facing a securities class action lawsuit, and investors who purchased the company's securities between July 14, 2023 and July 16, 2024 may be eligible for compensation. The deadline to join the lawsuit is February 24, 2025.GlobeNewswire Inc. · Feb 22, 2025

to start trading

CR

CRBUCaribou Biosciences, Inc. Common Stock

CRBU

Pay with—

Available Balance0.00

Your PositionYou don't own any CRBU yet.

Related Tickers

Earnings